Evidence map›Paper›PMID 41970713›Full record

ReviewInnovation (Cambridge (Mass.))2026

Unlocking new frontiers in bioimaging: The power of FLIM-AIE integration.

Sofía Blas-Gómez, Carlos Alonso-Moreno, Andrés Garzón-Ruiz, Iván Bravo

Abstract readReview
In one paragraph

Review in Innovation (Cambridge (Mass.)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sofía Blas-GómezUnidad nanoDrug, Facultad de Farmacia de Albacete, Departamento de Química Física, Universidad de Castilla-La Mancha, 02071 Albacete, Spain.
Carlos Alonso-MorenoUnidad nanoDrug, Facultad de Farmacia-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Departamento de Química Inorgánica, Orgánica y Bioquímica, Universidad de Castilla-La Mancha, 02071 Albacete, Spain.
Andrés Garzón-RuizUnidad nanoDrug, Facultad de Farmacia de Albacete, Departamento de Química Física, Universidad de Castilla-La Mancha, 02071 Albacete, Spain.
Iván BravoUnidad nanoDrug, Facultad de Farmacia de Albacete, Departamento de Química Física, Universidad de Castilla-La Mancha, 02071 Albacete, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The frontiers of bioimaging encompass cutting-edge technologies and methodologies that enhance the visualization, analysis, and interpretation of biological structures and processes with unprecedented precision. In this context, fluorescence lifetime imaging microscopy (FLIM) has emerged as a powerful technique that enables quantitative and concentration-independent imaging by measuring the fluorescence decay time of molecular probes. Unlike intensity-based fluorescence methods, FLIM provides robust data on molecular interactions, environments, and biomarker presence, making it invaluable for bioimaging. However, its widespread adoption remains constrained by technical complexity, the high cost of instrumentation, and the underdevelopment of fluorescence lifetime probes with AIE characteristics. A promising solution to these challenges lies in aggregation-induced emission (AIE) fluorophores, which overcome issues such as aggregation-caused quenching and photobleaching. Despite their potential, AIE fluorophores have been rarely integrated with FLIM, leaving a significant gap in bioimaging research. Integrating FLIM with AIE probes could revolutionize bioimaging, enabling precise, stable, and environment-sensitive lifetime imaging for diagnostics, metabolism, and live-cell monitoring. In this perspective, we examine the potential of FLIM-AIE integration in bioimaging, highlighting its advantages, identifying key barriers, and proposing strategies to promote its use in biomedical research. We highlight the critical role of interdisciplinary collaboration, enhanced training programs, and targeted funding initiatives in accelerating innovation in the field of bioimaging.

Identifiers

PMID41970713
PMCPMC13069402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.